Anything relating to the treatment and therapy available for CML
BCR-ABL1 mutations are a common, well-characterized mechanism of resistance to imatinib as first-line treatment of chronic myeloid leukemia in chronic phase (CML-CP). Less is known about mutation development during first-line treatment with dasatinib and nilotinib, despite increased use because of higher response rates compared with imatinib.
Armed with all this information, how can you help your body make the most optimal response possible to your TKI therapies?
Here’s what you need to know about the treatment options you are likely to encounter.
A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With CML or Ph+ ALL
De-Escalation & Stopping Treatment of Imatinib, Nilotinib or sprYcel in CML
A small retrospective study of heavily pretreated patients with chronic myeloid leukemia (CML) found bosutinib to be a good option in the fourth-line setting.